Use of biochemical markers to monitor changes in bone turnover in cynomolgus monkeys.
The ovariectomized old cynomolgus monkey is a recognized model of human osteoporosis, and the same species can be used for the assessment of the efficacy and potential toxicity of agents intended to prevent or treat osteoporosis. Several assays have been developed that can measure the same biochemical markers of bone turnover as are used in human patients for the diagnosis and treatment follow-up of bone-related diseases, including osteoporosis. The aim of the present study was to describe the results obtained with these assays in normal control monkeys, their variations with age and sex, and their sensitivity in monitoring the bone turnover induced by ovariectomy in old skeletally mature cynomolgus monkeys. Seven old cynomolgus monkeys were bilaterally ovariectomized and 13 age-matched monkeys were sham-operated. Bone mineral density and biochemical markers were measured before and at regular intervals after surgery for up to 20 months. Total alkaline phosphatase (total ALP), bone-specific alkaline phosphatase isoenzyme (bone ALP) and osteocalcin (OC) were highly correlated to the decrease in bone mineral density (BMD) induced by ovariectomy. Deoxypyridinoline (DPD) measured by enzyme-linked immunoassay was insensitive to the bone resorption induced by ovariectomy, but cross-linked N-telopeptide (NTX-I) was higher in ovariectomized monkeys than in control monkeys. These results demonstrate that reliable biochemical parameters are available to adequately monitor and provide insight into osteoclastic bone resorption and osteoblastic bone formation, the two components of bone turnover in this animal model, and can thus be used to assess the efficacy and toxicity of potential therapeutic agents.
Legrand
Jean-Jacques
JJ
Beaufour-Ipsen, Paris, France. jean-jacques.legrand@beaufour-ipsen.com
Fisch
Cecile
C
Guillaumat
Pierre-Olivier
PO
Pavard
Jean-Marc
JM
Attia
Mahmoud
M
De Jouffrey
Stephane
S
Claude
Jean-Roger
JR
D000818:Animals; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects; D001846:Bone Development / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000378:metabolism / Q000473:pathology; D001862:Bone Resorption / Q000188:drug therapy / Q000473:pathology; D001842:Bone and Bones / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D010052:Ovariectomy; D012016:Reference Values
D015415:Biomarkers